Ark Therapeutics Group PLC Cancellation and Publication of Prospectus (0106G)
February 26 2015 - 11:00AM
UK Regulatory
TIDMAKT
RNS Number : 0106G
Ark Therapeutics Group PLC
26 February 2015
ARK THERAPEUTICS GROUP PLC
Cancellation and Publication of Prospectus
London, UK, 26 February 2015 (LSE: AKT): Ark Therapeutics Group
plc ("Ark" or the "Company") announces that, following completion
of the acquisition of Premier Veterinary Group Limited on 5
February 2015, constituting a reverse takeover under the Listing
Rules, the Company has published a prospectus (the "Prospectus") in
connection with the requirement for it to re-apply for listing of
its entire issued share capital to the standard listing segment of
the Official List of the UK Listing Authority and admission to
trading on London Stock Exchange plc's main market for listed
securities ("Admission").
It is expected that Admission will become effective and that
dealings in the Company's ordinary shares on the London Stock
Exchange's main market will re-commence at 08.00 am on 27 February
2015. The Company's TIDM code will be PVG and, on Admission, there
will be 13,951,773 ordinary shares of 10 pence each in issue.
Therefore, on Admission, the total number of voting rights in the
Company is 13,951,773.
The above figure 13,951,773 may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, Ark under the FCA's Disclosure and Transparency
Rules.
Copies of the Prospectus are available from the registered
office of the Company at 11 Staple Inn, London WC1V 7QH.
A copy of the Prospectus will also be available for inspection
shortly at the Financial Conduct Authority's National Storage
Mechanism which can be accessed at www.morningstar.co.uk/uk/NSM and
on the Company's website http://www.arktherapeutics.com.
For further information please contact:
Ark Therapeutics Group plc Tel: +44(0)203 755 5160
Iain G Ross, Non-Executive Chairman
Susan Steven, Non-Executive Director
The contents of this announcement have been prepared by and are
the sole responsibility of the Company.
This announcement includes "forward-looking statements" which
include all statements other than statements of historical facts,
including, without limitation, those regarding Ark's financial
position, business strategy, plans and objectives of management for
future operations, and any statements preceded by, followed by or
that include forward-looking terminology such as the words
"targets", "believes", "estimates", "expects", "aims", "intends",
"will", "can", "may", "anticipates", "would", "should", "could" or
similar expressions or the negative thereof. Such forward-looking
statements involve known and unknown risks, uncertainties and other
important factors beyond Ark's control that could cause the actual
results, performance or achievements of Ark to be materially
different from future results, performance or achievements
expressed or implied by such forward-looking statements. Such
forward-looking statements are based on numerous assumptions
regarding Ark's present and future business strategies and the
environment in which Ark will operate in the future. These
forward-looking statements speak only as at the date of this
announcement. Ark expressly disclaims any obligation or undertaking
to disseminate any updates or revisions to any forward-looking
statements contained in this announcement to reflect any change in
Ark's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, readers are cautioned not to rely on
any forward-looking statement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
PDIPKADPPBKDFBB
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Apr 2023 to Apr 2024